Overview
SABS market data
Price History
SABS price chart
Valuation & Profitability
- P/E (TTM)
- 19.87 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.22 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.57 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.85 – $5.15 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $263.8 · P/B 1.18 · P/S 199.42.
Company News
SAB Biotherapeutics Receives Breakthrough T1D Grant To Advance SAB-142 Study In Newly Diagnosed Type 1 DiabetesBenzinga · Jul 7, 2026, 12:20 PM
Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13Benzinga · Jun 24, 2026, 6:55 PM
Chardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16Benzinga · Jun 17, 2026, 12:40 PM
Paychex To Rally More Than 39%? Here Are 10 Top Analyst Forecasts For MondayBenzinga · Jun 15, 2026, 2:00 PM
Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12Benzinga · Jun 15, 2026, 1:05 PM
Citigroup Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11Benzinga · May 22, 2026, 3:10 PM
This QuickLogic Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For WednesdayBenzinga · May 20, 2026, 12:55 PM
Jefferies Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11Benzinga · May 20, 2026, 12:40 PM
Rodman & Renshaw Reiterates Buy on SAB Biotherapeutics, Maintains $13 Price TargetBenzinga · May 11, 2026, 9:35 AM